Study details
Enrolling now
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
Massachusetts General Hospital
NCT IDNCT07236190ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 1.5 years
Ages
55+
Locations
1 site in MA
About this study
Researchers are testing a treatment called NPC1 to see if it affects biomarkers related to Alzheimer's disease in adults with signs of the disease. The trial will last 546 days and involve approximately 40 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NPC1
- 2.Take NPC1-Placebo/Control
PhasePhase 1/Phase 2
Primary goalSafety and Tolerability of NPC1
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Safety and Tolerability of NPC1
Body systems
Neurology